Astellas Pharma Licenses Promising Gene Therapy KT430 from Kate Therapeutics Amidst Clinical Hurdles
Portfolio Pulse from Vandana Singh
Astellas Pharma has licensed gene therapy KT430 from Kate Therapeutics for X-linked myotubular myopathy (XLMTM), a rare muscle disorder. This follows safety issues with Astellas' AT132 gene therapy, which led to a clinical hold from the FDA. Kate Therapeutics has also raised $51 million in a Series A financing round.
June 08, 2023 | 4:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Astellas Pharma licenses gene therapy KT430 from Kate Therapeutics for XLMTM, following safety issues with its AT132 therapy. Kate Therapeutics raises $51 million in Series A financing.
Astellas Pharma's decision to license KT430 from Kate Therapeutics is a positive move for the company, as it seeks to address the rare muscle disorder XLMTM. The previous safety issues with Astellas' AT132 therapy led to a clinical hold from the FDA, hindering its progress. Licensing KT430 could help Astellas overcome these hurdles and potentially lead to a successful treatment for XLMTM. This news, combined with Kate Therapeutics' successful Series A financing round, is likely to have a positive short-term impact on ALPMF's stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Astellas Pharma licenses gene therapy KT430 from Kate Therapeutics for XLMTM, following safety issues with its AT132 therapy. Kate Therapeutics raises $51 million in Series A financing.
Astellas Pharma's decision to license KT430 from Kate Therapeutics is a positive move for the company, as it seeks to address the rare muscle disorder XLMTM. The previous safety issues with Astellas' AT132 therapy led to a clinical hold from the FDA, hindering its progress. Licensing KT430 could help Astellas overcome these hurdles and potentially lead to a successful treatment for XLMTM. This news, combined with Kate Therapeutics' successful Series A financing round, is likely to have a positive short-term impact on ALPMY's stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100